May 28 (Reuters) - GlaxoSmithKline PLC:
* GSK - ANNOUNCES INTENTION TO PRODUCE 1 BILLION DOSES OF PANDEMIC VACCINE ADJUVANT IN 2021 TO SUPPORT MULTIPLE COVID-19 VACCINE COLLABORATIONS
* GSK - ANNOUNCES INTENTION TO PRODUCE 1 BILLION DOSES OF PANDEMIC VACCINE ADJUVANT IN 2021 TO SUPPORT MULTIPLE COVID-19 VACCINE COLLABORATIONS
* GSK - CONFIRMED ITS INTENTION TO MANUFACTURE 1 BILLION DOSES OF ITS PANDEMIC VACCINE ADJUVANT SYSTEM, IN 2021
* GSK - WILL MANUFACTURE, FILL AND FINISH ADJUVANT FOR USE IN COVID-19 VACCINES AT SITES IN UK, US, CANADA AND EUROPE
* GSK - OVERALL GSK DOES NOT EXPECT TO PROFIT FROM SALES OF ITS PORTFOLIO OF COLLABORATIONS FOR COVID-19 VACCINES MADE DURING THIS PANDEMIC PHASE
* GSK - IS IN DISCUSSIONS WITH GOVERNMENTS AND GLOBAL INSTITUTIONS ABOUT FUNDING FOR PRODUCTION AND SUPPLY OF ADJUVANT
* GSK - OVERALL GSK DOES NOT EXPECT TO PROFIT FROM SALES OF ITS PORTFOLIO OF COLLABORATIONS FOR COVID-19 VACCINES MADE DURING THIS PANDEMIC PHASE Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.